Condition: Oral Squamous Cell Carcinoma · Locally Advanced Head and Neck Carcinoma · Sponsor: Lai-ping Zhong
To evaluate the prognostic efficacy of neoadjuvant immunochemotherapy with tislelizumab, albumin paclitaxel and cisplatin followed by radical surgery and adjuvant therapy compared with standard therapy for patients with locally advanced and resectable oral squamous cell carcinoma.
This description comes directly from the study's public registry record.
Lai-ping Zhong, MD, PhD · +862152888915 · zhonglp@hotmail.com
Ying-ying Huang, MD · +862152889999 · kqyxyhyy@163.com
Always discuss trial participation with your own doctor first.
| Huashan Hospital, Fudan University | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06258811